Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Caresafe has developed a self-sanitizing surface coating system that creates conti...
Caresafe has developed a self-sanitizing surfac...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Eliot's produces peanut and nut butters featuring US grown nuts based in Portland ...
Eliot's produces peanut and nut butters featuri...
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused o...
Onconova Therapeutics, Inc. is a Phase 3-stage ...
Lonza is an integrated solutions provider that creates value along the Healthcare ...
Lonza is an integrated solutions provider that ...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
Join the National Investor Network and get the latest information with your interests in mind.